After speaking with technology, I feel my iQ went up 50%. They listen and explain the back-end methodology so it is comprehendible.
Client services is extremely responsive. Whenever I have questions, I receive a thorough response within hours.
With this Qforma’s roadmap, we have greater perspective into our customers and their business; both with customer prescribing habits and peer to peer relationships.
Founders, Leaders, Innovators
What started out as a seed of an idea has quickly grown around, over and through any limitation or conservative expectation in it’s path. Qforma’s executive team provides decades of industry experience and scientific innovation, fostering steady healthy growth. Often spotted with rolled sleeves, out in the field or developing algorithms, they stay involved, making things happen. Fostering growth and success for our clients and Qforma.
A pioneer in leveraging social analytics to drive value for life sciences companies, Kilian has developed innovative knowledge-based solutions for medical, marketing, sales and market access clients across the globe.
In 2005, Kilian co-founded Mederi AG, a Frankfurt-based network intelligence provider. In just six years, Kilian helped build the company into a leading source of analytic solutions used by eight of the top 10 pharma companies worldwide. In 2012, the company merged with Skila – a fully managed Solutions-as-a-Service (SaaS) consultancy – and Kilian moved to the United States to take the helm. Upon the merger with Qforma in June 2013, Kilian was asked to stay on as CEO.
Kilian has published several articles and co-authored a book about stochastic optimization.
Andy Rankin has more than 20 years experience in pharma, biotech and life science services and consulting environments with operational and leadership roles ranging from exploratory through to late-stage drug development , successful global regulatory approval and product launch. Andy’s global pharma leadership roles in Pfizer and Teva gained him In depth drug development experience across a range of therapeutic areas from Ph1 to 4, including renal, cardiovascular, urology and most recently leading programs and recognised expertise in auto-immune, neurology, oncology, pain and biosimilars. He is also an experienced consultant and clinical advisor to pharmaceutical start-up, biotechs and specialty pharma on clinical development strategy and program/trial design. Most recently at Prescient Healthcare, NJ, Andy worked with multiple clients adding value through strategic insight and evidence-based solutions at key milestones, decision and inflection points, including strategies for approaching product launch and patent expiration. He has been an invited speaker at recent US and International conferences, including DIA, addressing biosimilar drug development and pharmaceutical manufacturers’ response to product genericisation.
Robert has been with Qforma since its inception, where he was instrumental in developing its analytics and software.
Despite being born and raised in Manchester, England, Robert failed to pledge allegiance to either of its football teams. He received his MA in physics from Oxford University in 1983, his Ph.D. in 1987 and his MBA in 2000. He was included in PharmaVoice magazine’s “100 most inspiring People in Life Sciences” in 2012.
Ed Mendham has 20 years’ experience in progressive financial and accounting roles. Before joining Qforma, he served as Vice President, Finance for Advanced Health Media (AHM), a provider of software solutions, sales force logistics and outsourced speaker bureau management for the pharmaceutical industry. He was responsible for overseeing corporate financial planning and strategy and brought structure and process to the company’s financial functional areas. Prior to his role at AHM, Ed had served in various financial/accounting roles at JDS Uniphase (fiber optic manufacturer). Ed has an MBA from Rider University and is also a CPA.